Amylin Pharmaceuticals has posted total revenues of $174.13m, which includes net product sales of $172.3m, for the first quarter 2010, compared to $180.4m for the year ago period. Operating loss was 32.8m, compared to $45.55m for the year ago period.
Net product sales of $172.3m for the quarter include $149.8m for Byetta (exenatide) injection and $22.5m for Symlin (pramlintide acetate) injection. This compares to net product sales of $179.3m, consisting of $157.7m for Byetta and $21.6m for Symlin for the same period in 2009.
Daniel Bradbury, president and CEO of Amylin, said: “With the submission of our Bydureon response this week, we are preparing to make this revolutionary treatment option available this year to the millions of patients living with type 2 diabetes.
“We remain focused on driving revenue from our currently marketed products, Byetta and Symlin, and continue to exercise financial discipline so that we remain on track to generate sustainable positive operating cash flow by year end.”